Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is an open-label trial of treatment with ALZ-801.
- EligibilityCriteria: Inclusion Criteria:  Subject has completed the Week 78 of the Phase 3 core study (ALZ-801-AD301) while on study drug. Subject has a reliable study partner who has sufficient contact with the subject to be able to provide accurate information about the subject's cognitive and functional abilities.  Exclusion Criteria:  Significant worsening of medical conditions that may preclude completion of this study. Evidence of symptomatic or new moderate-severe radiologic ARIA at baseline. Has received (or plans to receive) amyloid antibodies since completing Phase 3 core study (ALZ-801-AD301). Subject taking any prohibited medications per protocol. - HealthyVolunteers: No - Gender: All - MinimumAge: 50 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult